DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations

Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Meningitis; Meningococcal Infection

Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® (Biological); Meningococcal Group C Conjugate vaccine: MenC (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: Sanofi Pasteur, a Sanofi Company

Official(s) and/or principal investigator(s):
Medical Dierctor, Study Director, Affiliation: Sanofi Pasteur SA

Summary

The purpose for this study is to demonstrate the safety and immunogenicity of two doses of Menactra administered between 12 and 18 months of age and concomitantly with routine immunization with two different provincial schedule Primary Objectives:

- To describe the immunogenicity of Menactra administered concomitantly with routine

immunizations at 12 and 18 months in nave or Menjugate-primed (MenC-primed) infants (measured by serum bactericidal assay using baby rabbit complement [SBA-BR])

- To describe the immunogenicity of MenC administered concomitantly with routine

immunizations at 12 months of age (measured by SBA-BR) Secondary Objectives: Safety

- To describe the safety profile of Menactra® and MenC vaccines after each dose when

given concomitantly with routine immunization. Immunogenicity

- To describe the immunogenicity of both vaccines using serum bactericidal assay using

human complement [SBA-HC]

- To describe the immunogenicity of Pediacel administered at 18 months.

Clinical Details

Official title: Safety and Immunogenicity of Two Doses of Menactra (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome:

Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.

Number of Participants With Serum Bovine Albumin Baby Rabbit Titers of ≥ 1:8 Following Vaccination With Either a Dose of Menactra Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.

Secondary outcome:

Geometric Mean Titers of Serum Bovine Albumin Human Complement Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.

Number of Participants With Serum Bovine Albumin Human Complement Titers of ≥ 1:8 Following Vaccination With Either a Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age.

Geometric Mean Titers of Antibodies to Pediacel® Vaccine Antigens in Participants That Received a Dose of Menactra® at 12 and 18 Months of Age, Respectively, and a Booster Dose of Pediacel® Vaccine at 18 Months of Age.

Summary of Participants With Booster Response for Pediacel® Vaccine Antigens After Vaccination With Pediacel® Vaccine (Menactra Vaccine Group)

Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With Either a Dose of Menactra Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate Vaccine at 12 Months of Age

Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With a Second Dose of Menactra Vaccine at 18 Months of Age

Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Any of the Study Vaccination

Detailed description: Participants depending on their groups will receive either two doses of Menactra vaccine concomitantly with the routinely recommended vaccines or one dose of MenC vaccine concomitantly with the routinely recommended vaccines and will be monitored for safety and immunogenicity. The duration of each subject's participation in the trial will be approximately 7 months.

Eligibility

Minimum age: 12 Months. Maximum age: 18 Months. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Aged 12 months (365 to 400 days) on the day of inclusion

- Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2. 5 kg

- Informed consent form has been signed and dated by the parent(s) or other legally

authorized representative

- Subject and parent/legal representative are able to attend all scheduled visits and

to comply with all trial procedures

- Group 1: Subject has received 3 primary vaccination doses of Pediacel as per routine

immunization schedule

- Group 3: Subject has received two doses of MenC vaccine at approximately 2 and 4

months of age as per Alberta immunization schedule. Exclusion Criteria:

- Participation in another clinical trial investigating a vaccine, drug, medical

device, or medical procedure in the 4 weeks preceding the first trial vaccination

- Planned participation in another clinical trial during the present trial period

- Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except

for influenza vaccination(s), which may be received at least two weeks before study vaccines

- Planned receipt of any vaccine in the 4 weeks following any trial vaccination

- Previous vaccination against Meningococcal disease OR

- Subject has previously received only one dose of MenC vaccine, or more than two doses

of MenC vaccine, or two doses of MenC vaccine with the most recent dose received in the past 6 months

- Receipt of blood or blood-derived products in the past 3 months which might interfere

with assessment of the immune response

- Known or suspected congenital or acquired immunodeficiency; or receipt of

immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

- Personal or maternal seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis

B, or Hepatitis C, as reported by the parent/legal representative

- History of documented invasive meningococcal disease

- At high risk for meningococcal disease during the trial

- Known systemic hypersensitivity to any of the vaccine components, or history of a

life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances

- History of contraindication to receipt of pertussis-containing vaccine

- Thrombocytopenia, as reported by the parent/legal representative, contraindicating

intramuscular vaccination

- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,

contraindicating intramuscular vaccination

- History of seizures

- Chronic illness that, in the opinion of the investigator, is at a stage where it

might interfere with trial conduct or completion

- History of Guillain-Barré Syndrome.

Locations and Contacts

Pierrefonds, Quebec H9H 4Y6, Canada
Additional Information

Starting date: May 2011
Last updated: June 16, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017